126 related articles for article (PubMed ID: 38685772)
1. Multiomics Analysis of Disulfidptosis Patterns and Integrated Machine Learning to Predict Immunotherapy Response in Lung Adenocarcinoma.
Liu J; Li H; Zhang N; Dong Q; Liang Z
Curr Med Chem; 2024 Apr; ():. PubMed ID: 38685772
[TBL] [Abstract][Full Text] [Related]
2. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma.
Zhang HB; Pan JY; Zhu T
Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882
[No Abstract] [Full Text] [Related]
3. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation.
Wang Y; Xu Y; Liu C; Yuan C; Zhang Y
Front Immunol; 2023; 14():1233260. PubMed ID: 37799714
[TBL] [Abstract][Full Text] [Related]
4. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma.
Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G
Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
7. The role of molecular subtypes and immune infiltration characteristics based on disulfidptosis-associated genes in lung adenocarcinoma.
Qi C; Ma J; Sun J; Wu X; Ding J
Aging (Albany NY); 2023 Jun; 15(11):5075-5095. PubMed ID: 37315289
[TBL] [Abstract][Full Text] [Related]
8. Molecular map of disulfidptosis-related genes in lung adenocarcinoma: the perspective toward immune microenvironment and prognosis.
Zhao F; Su L; Wang X; Luan J; Zhang X; Li Y; Li S; Hu L
Clin Epigenetics; 2024 Feb; 16(1):26. PubMed ID: 38342890
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
10. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
Liang H; Li Y; Qu Y; Zhang L
Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
[TBL] [Abstract][Full Text] [Related]
11. Deciphering disulfidptosis: Uncovering a lncRNA-based signature for prognostic assessment, personalized immunotherapy, and therapeutic agent selection in lung adenocarcinoma patients.
Ma C; Zhao H; Sun Y; Ding W; Wang H; Li Y; Gu Z
Cell Signal; 2024 May; 117():111105. PubMed ID: 38369264
[TBL] [Abstract][Full Text] [Related]
12. Identification of a disulfidptosis-related genes signature for prognostic implication in lung adenocarcinoma.
Huang J; Zhang J; Zhang F; Lu S; Guo S; Shi R; Zhai Y; Gao Y; Tao X; Jin Z; You L; Wu J
Comput Biol Med; 2023 Oct; 165():107402. PubMed ID: 37657358
[TBL] [Abstract][Full Text] [Related]
13. Identification of disulfidptosis-related subtypes and development of a prognosis model based on stacking framework in renal clear cell carcinoma.
Peng K; Wang N; Liu Q; Wang L; Duan X; Xie G; Li J; Ding D
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13793-13810. PubMed ID: 37530800
[TBL] [Abstract][Full Text] [Related]
14. Investigating the prognostic value of constructing disulfidptosis-related gene models for lung adenocarcinoma patients.
Luo M; Liu RZ; Li YJ; Zhang SD; Wu ZY
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9569-9585. PubMed ID: 37916324
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a disulfidptosis and disulfide metabolism-related risk index for predicting prognosis in lung adenocarcinoma.
Zhong L; Chang W; Luo B; Gao W; He H; Fang M; Li H; Wen Z; Chen Y
Cancer Cell Int; 2024 Jan; 24(1):2. PubMed ID: 38167017
[TBL] [Abstract][Full Text] [Related]
16. Leveraging a gene signature associated with disulfidptosis identified by machine learning to forecast clinical outcomes, immunological heterogeneities, and potential therapeutic targets within lower-grade glioma.
Zhou Y; Cao Y; Liu W; Wang L; Kuang Y; Zhou Y; Chen Q; Cheng Z; Huang H; Zhang W; Jiang X; Wang B; Ren C
Front Immunol; 2023; 14():1294459. PubMed ID: 38162649
[TBL] [Abstract][Full Text] [Related]
17. A novel disulfidptosis-related prognostic gene signature and experimental validation identify ACTN4 as a novel therapeutic target in lung adenocarcinoma.
Xie K; Wang B; Pang P; Li G; Yang Q; Fang C; Jiang W; Feng Y; Ma H
Cancer Biomark; 2024 Feb; ():. PubMed ID: 38517776
[TBL] [Abstract][Full Text] [Related]
18. Integrated multiomic analysis reveals disulfidptosis subtypes in glioblastoma: implications for immunotherapy, targeted therapy, and chemotherapy.
Yang X; Cai Z; Wang C; Jiang C; Li J; Chen F; Li W
Front Immunol; 2024; 15():1362543. PubMed ID: 38504986
[TBL] [Abstract][Full Text] [Related]
19. A programmed cell death-related model based on machine learning for predicting prognosis and immunotherapy responses in patients with lung adenocarcinoma.
Zhang Y; Wang Y; Chen J; Xia Y; Huang Y
Front Immunol; 2023; 14():1183230. PubMed ID: 37671155
[TBL] [Abstract][Full Text] [Related]
20. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]